The Defense Appropriations Committee of the U.S. House of Representatives passed a bill allocating $5 million in new funding for a peer-reviewed Lupus Medical Research Program on May 17. The program, included in a 2017 Defense Appropriations spending bill, is to be operated by the U.S. Defense Department. A…
Researchers have identified an enzyme called SHP-2 whose levels are significantly increased in blood samples of lupus patients and in systemic lupus erythematosus (SLE) mouse models, which can become a potential therapeutic target for patients suffering from this disease. The study, “Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus…
Today — Wednesday, May 18 — the six Lupus Agencies of New York State will be guests in the New York State Senate and Assembly as both houses recognize May as the 8th annual Lupus Awareness Month in the state. Legislative sponsors of the event are State Sen. Joseph Griffo…
The U.S. National Institute of Allergy and Infectious Disease (NIAID) has awarded $225,000 to Karyopharm Therapeutics to advance the development of its SINE nuclear transport compound, KPT-350, to treat neurological, inflammatory and autoimmune diseases. The grant will be used in preclinical trials of the compound as a treatment for systemic lupus erythematosus (SLE), which will…
Disrupted neuroimmune signaling contributes to cognitive problems in neuropsychiatric systemic lupus erythematosus (SLE), according to a study presented at the Congress of Clinical Rheumatology 2016 Annual Meeting, reported by Healio Rheumatology. These new insights into the molecular mechanisms of lupus might provide targets for the development of therapies for…
Findings from a large “Treat-to-Target” (T2T) study of systemic lupus erythematosus (SLE), focusing on patient and disease characteristics, and factors influencing a low disease activity state — associated with better long-term outcomes — were presented at the recent Australian Rheumatology Association Annual Scientific Meeting in Darwin. Treat-to-Target (T2T), an approach used for the design…
Lupus patient organizations are working to launch the World Lupus Federation (WLF), a new coalition aiming to improve life for the more than five million lupus patients worldwide. The WLF will facilitate the efforts of some 200 national groups to promote lupus education, awareness, and advocacy. New members of the WLF’s International Steering Committee are…
Lupus, also known as systemic lupus erythematosus (SLE), is difficult to diagnose and a challenge to treat, with a range of symptoms and no known cause or cure. But treatment options exist, including therapies being studied at Yale School of Medicine in New Haven, Connecticut. YaleNews’s Ziba Kashef recently interviewed Dr. Lenore Buckley —…
Today, May 10, is World Lupus Day, and to mark the day, the newly launched World Lupus Federation (WLF) undertook its first global initiative — releasing the results of one of the largest global surveys ever conducted into public awareness of and attitudes toward lupus. The online, six-question survey, conducted March…
Researchers developed a new monoclonal antibody against specific cells and molecules involved in systemic lupus erythematosus (SLE) that has shown potential both in vitro and in vivo studies. The findings have led the scientists to believe the antibody is ready for clinical testing in people as a potential new therapeutic agent. The study, by researchers at…